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Despite advances in pharmacogenetics, the majority of heritability for treatment response 
cannot be explained by common variation, suggesting that factors such as epigenetics 
may play a key role. Regulatory genes, such as those involved in DNA methylation and 
transcriptional repression, are therefore excellent candidates for investigating antipsychotic 
treatment response. This study explored the differential expression of regulatory genes 
between patients with schizophrenia (chronic and antipsychotic-naïve first-episode 
patients) and healthy controls in order to identify candidate genes for association with 
antipsychotic treatment response. Seven candidate differentially expressed genes were 
identified, and four variants within these genes were found to be significantly associated with 
treatment response (DNMT3A rs2304429, HDAC5 rs11079983, and HDAC9 rs1178119 
and rs11764843). Further analyses revealed that two of these variants (rs2304429 and 
rs11079983) are predicted to alter the expression of specific genes (DNMT3A, ASB16, 
and ASB16-AS1) in brain regions previously implicated in schizophrenia and treatment 
response. These results may aid in the development of biomarkers for antipsychotic 
treatment response, as well as novel drug targets.
Keywords: schizophrenia, epigenetics, neuropsychiatric genetics, gene expression, treatment response
INTRODUCTION
The onset of schizophrenia is marked by a first psychotic episode, typically followed by subsequent 
relapse episodes, separated by intervals of remission (Lieberman et al., 2001). Diagnosis remains 
difficult due to a heterogeneity of symptoms as well as symptom overlap with other disorders 
(Tandon et al., 2009). Furthermore, treatment strategies are not optimal (Brandl et al., 2014), and it is 
estimated that approximately half of all patients with schizophrenia will not respond satisfactorily to 
antipsychotics (Lohoff and Ferraro, 2010), which are the mainstay of treatment and, as such, widely 
used. They are effective for positive symptoms (such as delusions and hallucinations); however, 
their efficacy for negative symptoms (such as apathy, anhedonia, and social withdrawal) is limited 
(Leucht and Davis, 2017). Moreover, antipsychotics are known to result in a number of adverse drug 
reactions (ADRs), including motor abnormalities (Chowdhury et al., 2011) and metabolic deficits 
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(Tandon et al., 2010). These ADRs are often severe and long 
lasting, resulting in reduced compliance and diminished positive 
outcomes (Brandl et al., 2014). Considering the high rate of non-
responders to treatment and the potential severe side effects of 
treatment, there is a clear need to improve our understanding of 
antipsychotic treatment response.
Pharmacogenetics, the study of the effects of genetic variation 
on treatment outcomes, has been moderately successful in 
explaining variability in inter-individual treatment response. 
Variation within the dopaminergic pathway has been extensively 
investigated, and several variants within dopamine receptor 
genes are associated with treatment response (Lencz et al., 2010) 
and ADRs (Bakker et al., 2008). In addition, variation within 
genes encoding drug-metabolizing enzymes has yielded similar 
findings of association (Lohoff and Ferraro, 2010; Brandl et al., 
2014). Larger hypothesis-free-driven genome-wide association 
studies (GWAS) have also associated common variation with 
antipsychotic treatment response (Liou et al., 2012; Zhang and 
Malhotra, 2013); however, there has been little validation or 
replication of these associations, and their biological relevance 
remains to be determined (Liou et al., 2012; Zhang and Malhotra, 
2013). In addition to these challenges, the majority of treatment 
response heritability is not explained by common variation, 
suggesting that other factors must also play a role (Manolio et al., 
2009). This underscores the complexity and multi-factorial nature 
of treatment response since common and rare genetic factors, 
environmental factors, and gene-environment interactions need 
to be considered (Manolio et al., 2009; Majchrzak-Celińska and 
Baer-Dubowska, 2017).
Epigenetics refers to molecular mechanisms that determine 
inherited cellular phenotypes without alteration of the 
genotype (Wu et al., 2012). These mechanisms include various 
molecular processes, such as histone modification, nucleosome 
remodeling, non-coding RNAs, and DNA methylation (Wu 
et al., 2012). Both unique and overlapping altered epigenetic 
modifications are associated with schizophrenia etiology 
and pathogenesis as well as antipsychotic treatment (Swathy 
and Banerjee, 2017). As such, an extremely complex, 
multi-directional relationship needs to be considered in 
studying the role of epigenetics in treatment response 
(pharmacoepigenetics), since genes that are implicated may be 
regulated by epigenetic modification independent of disease 
etiology, treatment outcomes, and/or ADRs (Kurita et al., 
2012; Melas et al., 2012; Tang et al., 2014; Majchrzak-Celińska 
and Baer-Dubowska, 2017). For example, alterations of DNA 
methylation profiles (Melas et al., 2012; Tang et al., 2014) and 
altered chromatin structure (Kurita et al., 2012) may influence 
treatment response.
Although specific gene–environment interactions 
are required for epigenetic modifications to occur, it is 
important to note that specific genes directly or indirectly 
produce proteins and other products necessary for these 
modifications. For example, the DNMT1 gene encodes for 
Dnmt1, which is responsible for the maintenance of existing 
methylation patterns during cell division (Bostick et al., 
2007), while DNMT3A and DNMT3B encode for the enzymes 
responsible for establishing de novo methylation patterns 
(Okano et al., 1999). Regulatory genes, such as those involved 
in DNA methylation and transcriptional repression, are 
therefore excellent candidates for investigation with regards 
to antipsychotic treatment response.
The aims of this study were, therefore, to identify candidate 
regulatory genes that may be involved in antipsychotic treatment 
response, and then to determine if variation within these genes is 
associated with treatment outcome. In order to address these aims, 
we first sought to identify regulatory genes that were differentially 
expressed between patients with schizophrenia (including 
chronically medicated patients and drug-naïve first-episode 
patients) and healthy controls. By identifying genes differentially 
expressed between the chronically medicated patients and both 
the drug-naïve first-episode patients and healthy controls, we 
identified a subset of candidate genes that may be implicated in 
treatment response independent of schizophrenia pathogenesis. 
Variation within these candidate genes was then investigated in 
an independent cohort for association with treatment response 
over time.
MATERIALS AND METHODS
An outline of the approach used to perform this study is provided 
in Figure 1.
Participants for Gene Expression Analyses
The cohort consisted of 20 unrelated, age-matched, and male 
South African participants of South African colored (SAC) 
descent [10 patients with schizophrenia (SCZ), 26.4 ± 7.9 
years old, and 10 healthy controls (CON), 26.5 ± 7.6 years 
old]. Patients with SCZ were further divided into two equal 
groups consisting of five first-episode patients (FES) (24.8 ± 
10.9 years old) and five chronic patients (CHR) (28.0 ± 4.1 
years old). The FES patients were recruited and sampled 
within 1 week of their first episode of psychosis and were 
subsequently administered flupenthixol decanoate (Fluanxol, 
Lundbeck, Copenhagen, Denmark). The CHR patients were 
recruited 6.2 ± 0.4 years after their first episode, and all were 
treated with flupenthixol decanoate (Fluanxol, Lundbeck, 
Copenhagen, Denmark) in addition to other psychotropic 
medications (Supplementary Table 1). All patients were 
diagnosed using the Diagnostic and Statistical Manual of 
Mental Diseases, Fourth Edition, Text Revision (DSM-IV TR) 
(American Psychiatric Association, 2000) diagnostic criteria 
for SCZ, schizophreniform disorder, or schizo-affective 
disorder. Written informed consent was obtained from all 
patients, or their caregivers, prior to the study, and ethical 
approval was granted by the Human Research and Ethics 
Committee (HREC), Faculty of Medicine and Health Sciences, 
Stellenbosch University (N13/08/115).
Total RNA Isolation and cDNA Synthesis
Whole blood was collected from all participants by venipuncture 
of a forearm vein into PAXgene Blood RNA tubes (Qiagen, 
California, USA), which were stored at −20°C until processed. 
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Total RNA was extracted using the PAXgene Blood RNA Kit 
IVD according to the manufacturer’s instructions (Qiagen, 
California, USA). All samples were eluted in 80 µl of elution 
buffer and stored at −80°C until further analysis. RNA yield and 
quality were assessed using an Agilent Model 2100 Bioanalyzer 
(Agilent Technologies, California, USA) and a DropSense 16 
spectrophotometer (TRINEAN, Belgium). All samples had 
260/280 > 2.0 and RIN > 7.0.
Reverse transcription was performed using the High-Capacity 
cDNA Reverse Transcription Kit with RNase Inhibitor (Applied 
Biosystems, California, USA), according to the manufacturer’s 
specifications. Briefly, for each sample, 100 ng of RNA was added 
to 2 μl of random and oligo (dT) primers in a final reaction of 
20 μl. These reaction tubes were then placed in the GeneAmp® 
PCR Systems 2700 (Applied Biosystems, California, USA) 
thermocycler at 25°C for 10 min, 37°C for 120 min, and 85°C for 
5 min to inactivate the reverse transcriptase enzyme. The cDNA 
samples were then stored at −20°C until analyzed.
Quantitative Real-Time PCR
Quantitative real-time PCR (qRT-PCR), to determine 
the relative mRNA abundance, was performed using the 
StepOnePlus Real-Time PCR System and SDS Software version 
2.3 (Applied Biosystems, California, USA). The commercially 
available fluorescence-based TaqMan® Human DNA 
Methylation and Transcriptional Repression microarray plates 
(Applied Biosystems, California, USA) were used to assess the 
relative mRNA content of 27 regulatory genes (Table 1). Each 
sample was analyzed in two independent experiments to control 
for experimental bias using the following PCR conditions: a 
10-min heat activation step (95°C) followed by 40 cycles of 15 s 
at 94°C and 1 min at 63°C. Fluorescence data, indicative of the 
amount of PCR product, was captured at each cycle. The relative 
mRNA concentrations were then calculated based on the cycle 
number that the threshold quantity of PCR product is obtained 
(Ct). The RefFinder online tool was used to assess the stability 
of potential housekeeping genes (https://www.heartcure.com.
au/reffinder) (Xie et al., 2012), and GAPDH was identified as 
the most stable. Ct values were therefore normalized to values 
of GAPDH and expressed relative to this control (Livak and 
Schmittgen, 2001).
Gene Expression Analyses
Differential gene expression between the CON and SCZ groups 
was determined using unpaired t-tests or Mann-Whitney U tests 
where appropriate. Additionally, one-way analysis of variance 
(ANOVA) and Tukey’s post hoc tests were used to determine 
differences between the CON, FES, and CHR groups. The false 
discovery rate (FDR) correction (Benjamini and Hochberg, 
1995) was used to correct for multiple testing in the CON vs. 
SCZ and CON vs. FES vs. CHR analyses (27 genes; FDR < 0.01). 
A significance threshold of p < 0.05 was used for the Tukey’s 
post hoc tests since these were only performed in the case of a 
significant (FDR < 0.01) ANOVA result. Candidate genes for 
genetic association analyses with treatment response were 
selected if they met the following three criteria: i) significant 
FIGURE 1 | A flow diagram outlining the approach used in this study. (A) The first arm of the study involves identifying differentially expressed genes between 
healthy controls and schizophrenia patients, further divided into drug-naïve first-episode patients and chronic patients. (B) Differentially expressed genes were 
then used as candidates for genetic association with antipsychotic treatment response in a drug-naïve FES cohort. FES, first episode schizophrenia; CHR, chronic 
schizophrenia; SCZ, schizophrenia; CON, healthy control; eQTLs, expression quantitative trait loci.
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differences in gene expression between the CHR and CON 
groups, ii) no significant differences in gene expression between 
the FES and CON groups, and iii) significant differences in gene 
expression between the CHR and FES groups.
Participants for Genetic Association 
Analyses
The patient cohort included 103 unrelated South 
African FES patients meeting DSM-IV TR (American 
Psychiatric Association, 2000) diagnostic criteria for SCZ, 
schizophreniform disorder, or schizo-affective disorder (80% 
SAC, 12% Xhosa, and 8% European descent) and have been 
described previously (Drogemöller et al., 2014; Chiliza et al., 
2015; Ovenden et al., 2017; O’Connell et al., 2018). All patients 
received treatment with flupenthixol decanoate (Fluanxol, 
Lundbeck, Copenhagen, Denmark), a long-acting injectable 
antipsychotic, according to a fixed protocol. Treatment 
response was assessed using the Positive and Negative 
Syndrome Scale (PANSS) (Kay et al., 1987) over a period of 
12 months, with measurements taken biweekly for the first 
6 weeks, and every 3 months thereafter. Written informed 
consent was obtained from all patients, or their caregivers, 
prior to the study, and ethical approval was granted by 
HREC, Faculty of Medicine and Health Sciences, Stellenbosch 
University (N06/08/148).
Genetic Association Analyses
Variants within these candidate genes, obtained from each 
National Center for Biotechnology Information gene page 
(https://www.ncbi.nlm.nih.gov/gene/), were mined from 
available genome-wide genotype data. All 103 FES patients 
described above were previously genotyped with the Infinium 
OmniExpressExome-8 Kit (Illumina, California, USA) in 
accordance with the standard Illumina protocol. Variants were 
excluded from downstream analysis if they exhibited high rates 
of missing genotype data (> 5%), if their minor allele frequency 
(MAF) was < 1% or if they showed departure from the Hardy 
Weinberg equilibrium (p < 1×10-4). For this study, only variants 
with a minor allele frequency greater than 5% and a call rate 
greater than 98% were included for the association analyses. 
Furthermore, only one representative variant was included when 
two or more variants were shown to be in linkage disequilibrium 
(LD, r2 > 0.6) with one another. In total, 274 variants were included 
for analyses. All processing of genetic data was performed using 
Plink v1.9 (Purcell et al., 2007; Purcell and Chang).
Association analyses were conducted in R (R Core Team, 
2017) using R packages lme4 (Bates et al., 2014) and lmerTest 
(Kuznetsova et al., 2016). Linear mixed-effects models were used to 
investigate the effect of genetic variants on change in PANSS scores 
for each subscale (positive, negative, and general) and total over the 
12-month period, adjusting for age, gender, proportion ancestry, 
TABLE 1 | Relative expression levels for DNA methylation and transcriptional repression genes between control participants and schizophrenia patients.
Gene CON SCZ p-value1 FDR1 FES CHR p-value2 FDR2 p-value3 p-value4 p-value5
B2M# 1.053 ± 0.364 1.115 ± 0.471 0.675 0.104 0.852 ± 0.396 1.411 ± 0.373 0.015 0.002 0.212 0.034 0.009
CH4 1.045 ± 0.316 1.457 ± 0.438 0.011 0.004 1.326 ± 0.368 1.604 ± 0.487 0.006 0.001 0.056 0.003 0.200
DNMT1 1.044 ± 0.314 1.421 ± 0.456 0.027 0.008 1.336 ± 0.429 1.517 ± 0.494 0.024 0.003 0.063 0.009 0.430
DNMT3A# 1.061 ± 0.380 1.392 ± 0.357 0.015 0.005 1.208 ± 0.210 1.599 ± 0.384 0.004 0.001 0.299 0.004 0.018
DNMT3B 1.064 ± 0.383 1.907 ± 0.870 0.001 0.001 1.621 ± 0.626 2.229 ± 1.029 0.001 0.001 0.011 0.001 0.156
HDAC1# 1.046 ± 0.338 1.239 ± 0.374 0.131 0.025 1.063 ± 0.205 1.436 ± 0.433 0.029 0.004 0.899 0.024 0.035
HDAC2 1.087 ± 0.452 1.339 ± 0.463 0.109 0.023 1.346 ± 0.471 1.331 ± 0.486 0.217 0.019 n.d. n.d. n.d.
HDAC3 1.037 ± 0.306 1.341 ± 0.359 0.016 0.005 1.173 ± 0.219 1.531 ± 0.402 0.034 0.004 0.084 0.026 0.264
HDAC4 1.067 ± 0.490 1.154 ± 0.301 0.124 0.025 1.037 ± 0.303 1.284 ± 0.256 0.312 0.026 n.d. n.d. n.d.
HDAC5# 1.045 ± 0.329 1.482 ± 0.369 0.012 0.004 1.370 ± 0.413 1.626 ± 0.265 0.004 0.001 0.165 0.006 0.035
HDAC6 1.053 ± 0.354 1.601 ± 0.557 0.109 0.023 1.401 ± 0.369 1.825 ± 0.666 0.379 0.030 n.d. n.d. n.d.
HDAC7 1.049 ± 0.330 1.427 ± 0.395 0.001 0.001 1.211 ± 0.324 1.669 ± 0.330 0.002 0.001 0.041 0.002 0.211
HDAC8 1.056 ± 0.371 1.309 ± 0.362 0.002 0.001 1.162 ± 0.221 1.498 ± 0.434 0.002 0.001 0.029 0.001 0.120
HDAC9# 1.049 ± 0.339 1.451 ± 0.441 0.006 0.003 1.274 ± 0.503 1.650 ± 0.263  <0.001  <0.001 0.250  <0.001 0.011
HDAC10 1.101 ± 0.590 1.274 ± 0.406 0.060 0.015 1.106 ± 0.331 1.463 ± 0.418 0.033 0.004 0.441 0.021 0.174
HDAC11 0.949 ± 0.354 1.286 ± 0.418 0.006 0.003 1.176 ± 0.335 1.409 ± 0.488 0.004 0.001 0.193  <0.001 0.078
HMBS 1.078 ± 0.459 1.346 ± 0.397 0.059 0.015 1.185 ± 0.427 1.526 ± 0.287 0.059 0.006 n.d. n.d. n.d.
MBD2 1.041 ± 0.316 1.199 ± 0.381 0.207 0.038 1.029 ± 0.334 1.390 ± 0.353 0.044 0.005 0.928 0.023 0.047
MBD3# 1.041 ± 0.314 1.618 ± 0.598 0.002 0.001 1.280 ± 0.300 1.998 ± 0.634  <0.001  <0.001 0.077  <0.001 0.008
MECP2 1.070 ± 0.438 1.233 ± 0.472 0.305 0.051 1.037 ± 0.387 1.452 ± 0.482 0.099 0.009 n.d. n.d. n.d.
RBBP4 1.052 ± 0.388 1.162 ± 0.299 0.109 0.023 1.086 ± 0.265 1.246 ± 0.329 0.430 0.033 n.d. n.d. n.d.
RBBP7 1.051 ± 0.356 1.717 ± 0.547 <0.001 <0.001 1.500 ± 0.438 1.962 ± 0.579  <0.001  <0.001 0.010  <0.001 0.082
RPLP0# 1.064 ± 0.412 1.198 ± 0.635 0.480 0.077 0.857 ± 0.531 1.582 ± 0.531 0.011 0.002 0.288 0.015 0.013
SAP18 1.047 ± 0.347 1.192 ± 0.379 0.242 0.042 1.056 ± 0.277 1.346 ± 0.436 0.137 0.012 n.d. n.d. n.d.
SAP30 0.931 ± 0.404 1.507 ± 0.685 0.012 0.004 1.644 ± 0.789 1.371 ± 0.591 0.030 0.004 0.034 0.126 0.535
SIN3A 1.057 ± 0.373 1.570 ± 0.404 0.001 0.001 1.482 ± 0.381 1.669 ± 0.430 0.002 0.001 0.012 0.002 0.357
TRDMT1 1.080 ± 0.428 1.127 ± 0.357 0.807 0.120 1.052 ± 0.330 1.225 ± 0.393 0.651 0.048 n.d. n.d. n.d.
Bold typeset indicates significant differences [false discovery rate (FDR) < 0.01 or p < 0.05]. Data are presented as mean ± standard deviation.
CON, control participants; SCZ, schizophrenia patients; FES, first episode schizophrenia patients; CHR, chronic schizophrenia patients; n.d., not determined.
1CON vs. SCZ, 2CON vs. FES vs. CHR, 3CON vs. FES, 4CON vs. CHR, 5FES vs. CHR. #Genes included for association analyses with treatment response.
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and baseline PANSS scores. Multiple modes of inheritance were 
investigated and the Bonferroni correction method was used to 
correct for multiple testing (274 variants, four modes of inheritance, 
four PANSS domains; threshold p = 1.14 × 10-5).
Bioinformatic Analyses
Significantly associated variants were identified for intronic 
variants only, which were assessed for potential functionality 
as brain-specific eQTLs by interrogating the BRAINEAC 
(www.braineac.org) (Ramasamy et al., 2014) and GTex (www.
gtexportal.org) (GTEx Consortium, 2013, GTEx Consortium, 
2015) online databases.
RESULTS
Relative Gene Expression Results
After the initial analysis, comparing gene expression between the 
CON and SCZ groups, 14 genes were shown to have significantly 
different expression between these groups. Specifically, the CH4, 
DNMT1, DNMT3A, DNMT3B, HDAC3, HDAC5, HDAC6, 
HDAC7, HDAC9, HDAC11, MBD3, RBBP7, SAP30, and SIN3A 
genes showed increased expression in the SCZ group when 
compared to the CON group (Table 1). When comparing the 
CON group to the FES and CHR groups, 19 genes were shown to 
be differentially expressed (Table 1). Post hoc analyses identified 
seven genes that were significantly over-expressed in the CHR 
group when compared to both the CON and FES groups.
For follow-up investigation as candidates for association with 
antipsychotic treatment response, seven genes were selected. 
Specifically, the B2M, DNMT3A, HDAC5, HDAC9, MBD2, 
MBD3, and RPLP0 genes were selected since the expression 
levels of these genes were significantly different between the 
CHR and CON groups and CHR and FES groups, respectively 
(Table 1, Figure 2). Furthermore, no significant differences in 
gene expression were identified for these genes when comparing 
the FES and CON groups (Table 1, Figure 2).
Genetic Association Results
Of the 274 variants investigated within the seven candidate 
genes, four were significantly associated with treatment 
response, as described by a change in PANSS scores over time, 
when considering correction for multiple testing (p < 1 × 10-5) 
(Table 2). All significant associations were identified with the 
PANSS-negative domain. Specifically, the DNMT3A rs2304429 
CC genotype was significantly associated with an improved 
treatment response (greater reduction in PANSS-negative scores 
per month) when compared to the TC genotype. The rate of 
PANSS-N score reduction was significantly faster over time (an 
additional 1.92% per month) in patients with the DNMT3A 
rs2304429 CC genotype when compared to patients with the TC 
genotype. The HDAC5 rs11079983 TT genotype was significantly 
associated with a poorer treatment response (less reduction in 
PANSS-negative scores per month) when compared to the CC 
genotype. Patients with the HDAC5 rs11079983 TT genotype 
had significantly slower rate of PANSS-N score reduction over 
time (less by 2.36% per month) when compared to patients 
with the CC genotype. Two variants within HDAC9 (rs1178119 
and rs11764843) were also significantly associated with poorer 
treatment response (less improved PANSS-negative treatment 
trajectory scores) as shown in Table 2. For HDAC9 rs1178119, 
patients with the GA genotype had a significantly slower rate 
of reduction in PANSS-N scores over time (less by 2.04% per 
month) than patients with the AA genotype. Presence of the 
HDAC9 rs1178119 G allele was also significantly associated with 
a slower rate of reduction in PANSS-N scores over time (less by 
1.52% per month per G allele). Similarly, a significantly slower 
rate of reduction in PANSS-N scores over time (less by 1.92% 
per month) was also identified for patients with the HDAC9 
rs11764843 CA genotype when compared to those with the AA 
genotype.
Bioinformatics
The variants significantly associated with change in PANSS 
scores were assessed using the BRAINEAC (Ramasamy et al., 
2014) and GTex (GTEx Consortium, 2013, GTEx Consortium, 
2015) databases. Two variants (rs2304429 and rs11079983) were 
identified as potential brain-specific eQTLs. The rs2304429 
variant was suggested by BRAINEAC to alter the expression of 
DNMT3A in particular brain regions—namely, the putamen 
(PUTM), the cerebellar cortex (CRBL), the temporal cortex 
(TCTX), and the medulla (MEDU). Specifically, the TT genotype 
was associated with reduced expression of DNMT3A in these 
brain regions. In addition, the HDAC5 rs11079983 variant was 
shown to alter the expression of ASB16 and ASB16-AS1 in the 
cerebellum when considering the GTex database. Specifically, the 
TT genotype is associated with reduced expression of ASB16 and 
increased expression of ASB16-AS1 when compared to the CC 
genotype, respectively. None of the other variants were identified 
as brain-specific eQTLs in the BRAINEAC or GTex databases.
DISCUSSION
We identified a number of DNA methylation and transcriptional 
repression genes to be significantly over-expressed in patients 
with SCZ, in first-episode and CHR, when compared to healthy 
controls (Table 1). Specifically, seven candidate regulatory genes 
were identified, including B2M, DNMT3A, HDAC5, HDAC9, 
MBD2, MBD3, and RPLP0, and variation within these genes was 
assessed for association with antipsychotic treatment response. 
Four variants were found to be significantly associated with 
poorer treatment trajectory in the PANSS-negative domain.
In this study, significant increases in the expression of 
DNMT1 and DNMT3A were identified between all patients with 
SCZ and controls; however, further analyses revealed that this 
increase was only present when considering the CHR patients 
and not in the FES patients. Increased DNMT1 and DNMT3A 
gene expression in the GABAergic neurons of SCZ patients 
has been previously identified (Zhubi et al., 2009), while the 
increased expression of DNMT1 was also established in the 
peripheral blood lymphocytes of patients with SCZ (Auta et al., 
2013). When considering these previous studies, it is interesting 
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to note that the mean ages of their study cohorts were 57 ± 11 
and 56 ± 18 (Zhubi et al., 2009) and 43.6 ± 10.3 (Auta et al., 
2013), respectively. Given the young age of onset of SCZ, it is 
likely that the patients in these cohorts are more indicative of 
chronic SCZ and that the results of this study therefore replicate 
these previous findings.
The expression of a number of HDAC genes (1–4, 6, and 9) 
was previously investigated in the prefrontal cortex of patients 
TABLE 2 | Variants significantly associated with treatment trajectory for the PANSS negative domain.
Gene Variant Mode Contrast Effect
(% change per 
month)
95% Confidence 
Interval
p-value
DNMT3A rs2304429 Genotypic TC vs CC 1.92 1.12 to 2.68 2.50 x10-6
HDAC5 rs11079983 Genotypic TT vs CC 2.36 1.32 to 3.36 8.41 x10-6
HDAC9 rs1178119 Genotypic GA vs AA 2.04 1.24 to 2.8 5.42 x10-7
Additive Each G 1.52 0.88 to 2.16 5.21 x10-6
rs11764843 Genotypic CA vs AA 1.92 1.16 to 2.68 1.22 x10-6
FIGURE 2 | The relative expression levels of B2M, DNMT3A, HDAC5, HDAC9, MBD2, MBD3, and RPLP0 in the SCZ, FES, and CHR groups when compared 
to the CON group. ***Significant after correction, versus CON group. #Significant after correction, versus FES group. Data is presented as mean ± standard error. 
Additional details available in Table 1.
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with SCZ (Sharma et al., 2008). Only HDAC1 was shown to 
have increased expression in patients with SCZ when compared 
to controls, while no significant differences in expression were 
identified for the other HDAC genes (Sharma et al., 2008). One 
possible explanation for the differences between these results 
and those of our study is that these patients were subject to a 
range of different medications, including typical and atypical 
antipsychotics, mood stabilizers (including valproic acid), 
antidepressants, stimulants, and sedatives which all may have 
an effect on the gene expression observed (Majchrzak-Celińska 
and Baer-Dubowska, 2017). Of the other differentially expressed 
genes in this study, SAP30 expression was previously investigated 
and no significant changes were identified (Vawter et al., 2006). 
These results highlight the need for well-defined and deep 
phenotyping when investigating the molecular etiologies of 
neuropsychiatric disorders since their molecular architecture is 
malleable to disorder progression as well as treatment and other 
environmental factors (Gurwitz and Pirmohamed, 2010).
Due to the nature of the genes investigated in this study, 
changes in gene expression that were identified are indicative 
of altered regulatory mechanisms in chronically medicated 
patients with SCZ (Table 1). The alteration of these regulatory 
mechanisms is likely the result of a combination of disease 
progression, antipsychotic medication (Swathy and Banerjee, 
2017), and the influence of other environmental factors through 
the process of epigenetics (Feil and Fraga, 2012). To further 
elucidate these complex interactions, gene expression differences 
between first-episode and CHR, as well as healthy controls, 
were assessed. Significantly increased expression of seven genes 
(B2M, DNMT3A, HDAC5, HDAC9, MBD2, MBD3, and RPLP0) 
was observed in patients with chronic SCZ, when compared 
to FES and healthy controls (Figure 2). These seven genes 
were selected as candidates for association with antipsychotic 
treatment response.
Novel associations were identified between variants within 
DNMT3A (rs2304429), HDAC5 (rs11079983), and HDAC9 
(rs1178119, rs11764843) and antipsychotic treatment response 
as defined by a change in PANSS scores over time (Table 2). 
Specifically, all four of these variants were associated with a 
significantly worse treatment trajectory in the negative PANSS 
symptom domain. Bioinformatics analyses of these variants 
revealed that two variants are predicted to exert functional 
changes as eQTLs. The DNMT3A rs2304429 and HDAC5 
rs11079983 variants were predicted to alter expression of specific 
genes in particular brain regions. Specifically, individuals with 
the rs2304429 CC genotype have increased DNMT3A gene 
expression in the PUTM, CRBL, TCTX, and MEDU when 
compared to individuals with the TC or TT genotypes. In 
addition, individuals with the HDAC5 rs11079983 TT genotype 
have reduced expression of ASB16 and increased expression 
of ASB16-AS1 in the cerebellum when compared to the CC 
genotype. In this study, the rs2304429 CC and rs11079983 CC 
genotypes infer improved treatment response indicating that 
the brain region-specific gene expression changes associated 
with these variants may play a role. From these results, it may be 
hypothesized that increased expression of DNMT3A, as result 
of the rs2304429 CC genotype, in the abovementioned brain 
regions may result in de novo methylation patterns (Okano 
et al., 1999) that result in increased efficacy of antipsychotic 
medication. Similarly, reduced expression of ASB16 and 
ASB16-AS1 in the cerebellum, in the presence of the rs11079983 
CC genotype, may result in altered ubiquitin-mediated pathways 
(Kohroki et al., 2005) and cytokine signaling (Babon et al., 2009) 
with beneficial effects when considering antipsychotic response. 
These brain regions have previously been implicated in SCZ 
(Hokama et al., 1995; Turetsky et al., 1995; Harrison, 2004; 
Yeganeh-Doost et  al., 2011; Williams et al., 2014; Tohid et al., 
2015) and suggested as targets for treatment (Buchsbaum et al., 
2003; Hugdahl et al., 2009; Mitelman et al., 2009; Parker et al., 
2014). These brain region-specific eQTLs should therefore be 
investigated as biomarkers and potential targets for antipsychotic 
treatment response.
The potential underlying mechanisms of action associated 
with the remaining two significant findings are not clear. 
Further studies investigating the exact role that these variants 
may have in antipsychotic treatment response is warranted. 
Furthermore, the novel associations identified in this study 
should be replicated and validated in additional independent 
cohorts. Moreover, the eQTL data presented were not generated 
from Sub-Saharan African-ancestry-related individuals and 
further studies are required to confirm whether the variants 
presented here have similar eQTL effects in populations of 
African-ancestry. Due to the small sample sizes used for the 
gene expression analyses in this study, these results should be 
interpreted with caution and require replication. Functional 
studies incorporating in situ and in vivo assays should also be 
considered for validation of these results. Moreover, the gene 
expression results presented in this study should be replicated 
in female patients with SCZ and controls.
In conclusion, this study identified significant differential 
expression of DNA methylation and transcriptional repression 
genes between FES with SCZ, chronically medicated patients with 
SCZ and healthy controls. Variants within specific differentially 
expressed genes were significantly associated with antipsychotic 
treatment response, and highlighted particular brain regions 
in which altered expression of specific genes may play a role in 
treatment outcome. These results may aid in the development 
of biomarkers for antipsychotic treatment response, as well as, 
novel drug targets, and treatment strategies.
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